PARP1 and acute lymphoblastic leukemia: TET1 expression that is dependent on PARP1 might be inhibited by PARP1 inhibitors such as Olaparib, resulting in the removal of 5hmC marks, which could lead to the development of a therapy route for T-ALL cells [206].